Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK099681, R03)
Takeda Pharmaceuticals U.S.A.
American Gastroenterological Association (Pfizer Award in IBD)
Crohn's and Colitis Foundation of America (Senior Research Award)
Received: 7 August 2019
Accepted: 7 July 2020
First Online: 11 July 2020
Change Date: 8 December 2020
Change Type: Update
Change Details: Open Access Funding note was added to backmatter text of the article. This article has been updated to correct this
Ethics approval and consent to participate
: The study was approved by Partners Human Research Committee, the Institutional Review Board of Partners HealthCare. All participants provided written informed consent before enrollment.
: Not applicable.
: HK receives research funding from Pfizer and Takeda Pharmaceuticals. HK has also received consulting fees from Abbvie and Takeda. KS receives research funding from Astra-Zeneca and Gelesis. None of the industry funding is related to the current study. The remaining contributing authors declare no potential competing interests.